rpl2502 Antibody

What is RPL22 and what are the validated applications for RPL22 antibody (25002-1-AP)?

Ribosomal protein L22 (RPL22) is a component of the 60S ribosomal subunit with a calculated molecular weight of 15 kDa, though typically observed at 15-18 kDa in experimental conditions. This antibody has been validated for multiple applications including Western Blot (WB), Immunoprecipitation (IP), and Immunofluorescence/Immunocytochemistry (IF/ICC) . The polyclonal nature of this antibody provides high sensitivity, recognizing multiple epitopes of the target protein, making it particularly useful for detection of endogenous protein levels. Published applications have demonstrated successful use in knockdown/knockout validation experiments, with at least 2 publications utilizing this approach .

What controls should be included when using RPL22 antibody in experimental procedures?

Proper experimental controls are essential for antibody validation. According to the International Working Group for Antibody Validation's "five pillars" approach, genetic strategies using knockout/knockdown techniques are highly recommended as controls for specificity . When using RPL22 antibody, researchers should include:

• Positive controls: Cell lysates from A431, HeLa, HepG2, or Jurkat cells where RPL22 expression has been confirmed

• Negative controls: Either RPL22 knockout cells (ideal) or siRNA knockdown samples

• Secondary antibody-only controls to assess background signal

• Loading controls (e.g., GAPDH, β-actin) for western blot applications

These controls align with the "genetic strategies" pillar of antibody validation, which emphasizes the importance of demonstrating specificity through loss of signal in knockout/knockdown samples .

How can researchers differentiate between specific binding and cross-reactivity when using RPL22 antibody?

Cross-reactivity assessment requires multiple complementary approaches. While the RPL22 antibody (25002-1-AP) demonstrates specificity in human samples, cross-reactivity assessment should follow these methodological steps:

• Orthogonal validation: Compare antibody results with antibody-independent techniques like mass spectrometry or RNA expression analysis

• Multiple antibody validation: Use independent antibodies targeting different epitopes of RPL22

• Recombinant expression: Overexpress tagged RPL22 to confirm antibody specificity against elevated target levels

• Immunocapture-MS validation: Perform immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody

These approaches follow the additional four "pillars" of antibody validation established by the International Working Group for Antibody Validation. In particular, the orthogonal strategy approach can identify cases where the antibody might be detecting related ribosomal proteins with similar structural features .

What methodological considerations are important for optimizing immunofluorescence applications?

Immunofluorescence optimization with RPL22 antibody requires careful attention to fixation, permeabilization, and signal amplification:

• Fixation optimization: Compare paraformaldehyde (4%, 10-15 minutes) with methanol fixation (-20°C, 10 minutes) to determine which better preserves the epitope

• Permeabilization protocol: For cytoplasmic ribosomal proteins like RPL22, moderate permeabilization (0.1-0.3% Triton X-100 for 5-10 minutes) is recommended

• Blocking buffer composition: Use 5% normal serum (from the species of secondary antibody origin) with 1% BSA to minimize non-specific binding

• Primary antibody dilution: Begin with 1:200 dilution in blocking buffer and incubate overnight at 4°C, then optimize as needed

• Signal-to-noise optimization: Include 0.1% Tween-20 in wash buffers and extend washing steps (4-5 washes, 5 minutes each)

The effectiveness of these protocols should be assessed in HeLa cells, which have been validated as a positive control for this antibody in IF applications .

How should researchers address unexpected molecular weight observations when using RPL22 antibody?

The RPL22 antibody detects a protein with calculated molecular weight of 15 kDa, but observed molecular weight typically ranges from 15-18 kDa . This discrepancy may result from:

• Post-translational modifications: Phosphorylation, methylation, or other modifications common in ribosomal proteins

• Alternative splicing: Expression of splice variants

• Sample preparation effects: Different lysis buffers or denaturation conditions

Methodological approach to address this issue:

• Include molecular weight markers spanning 10-25 kDa range for precise sizing

• Compare denaturing conditions (reducing vs. non-reducing, boiling time)

• Assess cell-type specific differences in observed molecular weight

• Consider lambda phosphatase treatment to determine if phosphorylation contributes to the size shift

• Run gradient gels (4-20%) to achieve better resolution in the low molecular weight range

What strategies can be employed to validate antibody specificity when knockout models are unavailable?

When genetic knockouts are unavailable for RPL22 validation, alternative methodological approaches include:

• siRNA knockdown: Transfect cells with RPL22-specific siRNA and confirm reduction in signal intensity

• Peptide competition: Pre-incubate antibody with immunizing peptide (if available) to block specific binding

• Orthogonal protein detection: Compare results with mass spectrometry-based detection or alternative antibodies

• Recombinant protein standards: Include titrations of purified RPL22 protein as quantitative controls

• Immunodepletion: Sequential immunoprecipitation to demonstrate depletion of the target protein from samples

These approaches adapt the "five pillars" validation concept to situations where knockout models are impractical. The orthogonal strategy, using protein detection methods that don't rely on antibodies, provides particularly strong validation when combined with knockdown approaches .

How can RPL22 antibody be integrated into multi-omics research approaches?

RPL22 antibody can be effectively incorporated into multi-omics workflows using these methodological approaches:

• Immunoprecipitation-mass spectrometry (IP-MS): Use the antibody (4.0 μg per 3.0 mg lysate) to pull down RPL22 and its interaction partners, followed by mass spectrometry identification

• ChIP-seq applications: Adapt chromatin immunoprecipitation protocols if investigating potential RNA-DNA interactions

• Ribosome profiling correlation: Compare RPL22 antibody-based localization with ribosome profiling data

• APEX proximity labeling: Combine with engineered peroxidase approaches for subcellular localization studies

• Single-cell Western blot: Adapt dilutions (starting with 1:250) for microfluidics-based single-cell protein analysis

The immunocapture-MS strategy, in particular, aligns with the fifth "pillar" of antibody validation and provides rich information about both specificity and biological function through interactome analysis .

What considerations are important when adapting RPL22 antibody protocols across different model organisms?

While RPL22 antibody (25002-1-AP) has been tested explicitly with human samples, cited reactivity includes mouse . When adapting protocols across species:

• Sequence homology assessment: Compare the immunogen sequence with the target organism's RPL22 sequence

• Pilot validation studies: Perform small-scale experiments with positive and negative controls from the target species

• Antibody dilution optimization: Usually require 2-5 fold adjustments from recommended human sample dilutions

• Species-specific blocking: Use serum from the target species to reduce background

• Cross-reactivity profiling: Test against lysates from knockout models if available in the target organism

This multi-step validation aligns with the "multiple antibody strategy" pillar by ensuring that antibody performance is consistent across experimental models .

What methodological steps ensure reproducible quantification using RPL22 antibody?

Quantitative applications of RPL22 antibody require strict standardization:

• Antibody lot testing: Validate each new lot against a reference sample to ensure consistent sensitivity

• Standard curve development: Generate standard curves using recombinant RPL22 protein

• Dynamic range determination: Establish the linear range of detection for each application

• Internal control normalization: Include invariant controls (housekeeping proteins) and normalize signal accordingly

• Technical replication strategy: Perform triplicate measurements with statistical analysis

These approaches address a key concern in antibody research: reproducibility across laboratories and experiments. Standardized protocols and thorough validation significantly improve inter-laboratory reproducibility of findings .

How should researchers interpret conflicting results between different antibody-based detection methods?

When discrepancies arise between different methods using RPL22 antibody (25002-1-AP):

• Application-specific epitope accessibility: Different methods (WB, IF, IP) may expose different epitopes

• Denaturation-dependent recognition: Compare native versus denatured conditions to assess epitope conformation requirements

• Buffer compatibility analysis: Systematically test buffer components that might interfere with antibody binding

• Antibody affinity determination: Measure binding kinetics in different application contexts

• Orthogonal validation prioritization: When conflicts persist, prioritize results confirmed by antibody-independent methods

The multiple antibody strategy from the "five pillars" approach is particularly valuable here, as consistent results across different antibodies targeting different epitopes provides strong validation .